Search
01/09/2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023)
Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, OJ, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03290-7. PMID:37556098. IF:2.800(Q2/5D).
01/09/2023
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Segura, PP, Quintela, NV, Garcia, MM, Berron, SD, Sarrio, RG, Gomez, JG, Castano, AG, Martin, LMN, Rubio, OG, Losada, EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:2.800(Q2/5D).
01/09/2023
SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
Serrano C., Álvarez R., Carrasco J.A., Marquina G., Martínez-García J., Martínez-Marín V., Sala M.Á., Sebio A., Sevilla I., Martín-Broto J.. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:2.800(Q2/5D).
31/08/2023
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
Garcia-Carbonero R., González Astorga B., Vidal Tocino R., Contreras Toledo D., Pericay C., Fernández Montes A., Falcó E., González Cordero M., Reina Zoilo J.J., Alonso V., Rodríguez Salas N., Gil-Raga M., Santos C., Páez D., Anton-Pascual B., Aguilar F., Morales P.. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:2.800(Q2/5D).
03/08/2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Macaulay V.M., Lord S., Hussain S., Maroto J.P., Jones R.H., Climent M.Á., Cook N., Lin, CC, Wang, SS, Bianchini D., Bailey M., Schlieker L., Bogenrieder T., de Bono J.. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6)DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6.400(Q1/2D).
01/08/2023
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).